nodes	percent_of_prediction	percent_of_DWPC	metapath
Fenoldopam—Myocardial ischaemia—Tamoxifen—pancreatic cancer	0.00881	0.0169	CcSEcCtD
Fenoldopam—Transaminases increased—Gemcitabine—pancreatic cancer	0.008	0.0153	CcSEcCtD
Fenoldopam—Myocardial ischaemia—Sunitinib—pancreatic cancer	0.00755	0.0144	CcSEcCtD
Fenoldopam—Creatinine increased—Tamoxifen—pancreatic cancer	0.00744	0.0142	CcSEcCtD
Fenoldopam—Creatinine increased—Sunitinib—pancreatic cancer	0.00637	0.0122	CcSEcCtD
Fenoldopam—Myocardial ischaemia—Irinotecan—pancreatic cancer	0.00622	0.0119	CcSEcCtD
Fenoldopam—Myocardial ischaemia—Fluorouracil—pancreatic cancer	0.00596	0.0114	CcSEcCtD
Fenoldopam—Creatinine increased—Gemcitabine—pancreatic cancer	0.00511	0.00979	CcSEcCtD
Fenoldopam—Leukocytosis—Fluorouracil—pancreatic cancer	0.00509	0.00975	CcSEcCtD
Fenoldopam—Injection site reaction—Gemcitabine—pancreatic cancer	0.00484	0.00926	CcSEcCtD
Fenoldopam—Nasal congestion—Sunitinib—pancreatic cancer	0.00483	0.00925	CcSEcCtD
Fenoldopam—Blood creatinine increased—Tamoxifen—pancreatic cancer	0.00482	0.00922	CcSEcCtD
Fenoldopam—Hypokalaemia—Erlotinib—pancreatic cancer	0.00463	0.00886	CcSEcCtD
Fenoldopam—Blood urea increased—Gemcitabine—pancreatic cancer	0.0046	0.0088	CcSEcCtD
Fenoldopam—Lactic dehydrogenase activity increased—Epirubicin—pancreatic cancer	0.00455	0.00872	CcSEcCtD
Fenoldopam—Cardiac failure—Sunitinib—pancreatic cancer	0.00451	0.00864	CcSEcCtD
Fenoldopam—Angina pectoris—Tamoxifen—pancreatic cancer	0.00433	0.00829	CcSEcCtD
Fenoldopam—Myocardial ischaemia—Docetaxel—pancreatic cancer	0.0043	0.00823	CcSEcCtD
Fenoldopam—Lactic dehydrogenase activity increased—Doxorubicin—pancreatic cancer	0.00421	0.00807	CcSEcCtD
Fenoldopam—Blood creatinine increased—Sunitinib—pancreatic cancer	0.00413	0.0079	CcSEcCtD
Fenoldopam—Blood lactate dehydrogenase increased—Epirubicin—pancreatic cancer	0.00401	0.00768	CcSEcCtD
Fenoldopam—Hypokalaemia—Sunitinib—pancreatic cancer	0.00401	0.00767	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Tamoxifen—pancreatic cancer	0.00391	0.00748	CcSEcCtD
Fenoldopam—Myocardial infarction—Tamoxifen—pancreatic cancer	0.00388	0.00744	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Erlotinib—pancreatic cancer	0.00387	0.0074	CcSEcCtD
Fenoldopam—Urinary tract infection—Tamoxifen—pancreatic cancer	0.00385	0.00737	CcSEcCtD
Fenoldopam—Myocardial infarction—Erlotinib—pancreatic cancer	0.00384	0.00736	CcSEcCtD
Fenoldopam—Transaminases increased—Epirubicin—pancreatic cancer	0.00383	0.00733	CcSEcCtD
Fenoldopam—Sweating—Tamoxifen—pancreatic cancer	0.0038	0.00727	CcSEcCtD
Fenoldopam—Oliguria—Docetaxel—pancreatic cancer	0.00375	0.00718	CcSEcCtD
Fenoldopam—Blood lactate dehydrogenase increased—Doxorubicin—pancreatic cancer	0.00371	0.0071	CcSEcCtD
Fenoldopam—Cardiac failure—Gemcitabine—pancreatic cancer	0.00362	0.00693	CcSEcCtD
Fenoldopam—Haemoglobin—Tamoxifen—pancreatic cancer	0.00358	0.00684	CcSEcCtD
Fenoldopam—Cardiac failure—Fluorouracil—pancreatic cancer	0.00356	0.00682	CcSEcCtD
Fenoldopam—Haemorrhage—Tamoxifen—pancreatic cancer	0.00356	0.00681	CcSEcCtD
Fenoldopam—Transaminases increased—Doxorubicin—pancreatic cancer	0.00354	0.00678	CcSEcCtD
Fenoldopam—Haemoglobin—Erlotinib—pancreatic cancer	0.00354	0.00677	CcSEcCtD
Fenoldopam—Haemorrhage—Erlotinib—pancreatic cancer	0.00352	0.00674	CcSEcCtD
Fenoldopam—Injection site reaction—Docetaxel—pancreatic cancer	0.00343	0.00657	CcSEcCtD
Fenoldopam—Blood creatinine increased—Irinotecan—pancreatic cancer	0.0034	0.00651	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Sunitinib—pancreatic cancer	0.00335	0.0064	CcSEcCtD
Fenoldopam—Orthostatic hypotension—Irinotecan—pancreatic cancer	0.00331	0.00634	CcSEcCtD
Fenoldopam—Blood creatinine increased—Gemcitabine—pancreatic cancer	0.00331	0.00634	CcSEcCtD
Fenoldopam—Hypokalaemia—Irinotecan—pancreatic cancer	0.0033	0.00632	CcSEcCtD
Fenoldopam—Flushing—Tamoxifen—pancreatic cancer	0.0033	0.00632	CcSEcCtD
Fenoldopam—Urinary tract infection—Sunitinib—pancreatic cancer	0.0033	0.00632	CcSEcCtD
Fenoldopam—Hypokalaemia—Gemcitabine—pancreatic cancer	0.00322	0.00616	CcSEcCtD
Fenoldopam—Bradycardia—Sunitinib—pancreatic cancer	0.0031	0.00594	CcSEcCtD
Fenoldopam—Haemoglobin—Sunitinib—pancreatic cancer	0.00306	0.00586	CcSEcCtD
Fenoldopam—Angina pectoris—Irinotecan—pancreatic cancer	0.00305	0.00585	CcSEcCtD
Fenoldopam—Haemorrhage—Sunitinib—pancreatic cancer	0.00305	0.00583	CcSEcCtD
Fenoldopam—Back pain—Tamoxifen—pancreatic cancer	0.003	0.00573	CcSEcCtD
Fenoldopam—Muscle spasms—Tamoxifen—pancreatic cancer	0.00298	0.0057	CcSEcCtD
Fenoldopam—Back pain—Erlotinib—pancreatic cancer	0.00296	0.00567	CcSEcCtD
Fenoldopam—Angina pectoris—Fluorouracil—pancreatic cancer	0.00293	0.0056	CcSEcCtD
Fenoldopam—Flushing—Sunitinib—pancreatic cancer	0.00283	0.00541	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Irinotecan—pancreatic cancer	0.00276	0.00528	CcSEcCtD
Fenoldopam—Myocardial infarction—Irinotecan—pancreatic cancer	0.00274	0.00525	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Gemcitabine—pancreatic cancer	0.00268	0.00514	CcSEcCtD
Fenoldopam—Sweating—Irinotecan—pancreatic cancer	0.00268	0.00513	CcSEcCtD
Fenoldopam—Myocardial infarction—Gemcitabine—pancreatic cancer	0.00267	0.00511	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Fluorouracil—pancreatic cancer	0.00264	0.00505	CcSEcCtD
Fenoldopam—Chest pain—Tamoxifen—pancreatic cancer	0.00264	0.00505	CcSEcCtD
Fenoldopam—Anxiety—Tamoxifen—pancreatic cancer	0.00263	0.00503	CcSEcCtD
Fenoldopam—Myocardial infarction—Fluorouracil—pancreatic cancer	0.00262	0.00502	CcSEcCtD
Fenoldopam—Sweating—Gemcitabine—pancreatic cancer	0.00261	0.005	CcSEcCtD
Fenoldopam—Chest pain—Erlotinib—pancreatic cancer	0.00261	0.00499	CcSEcCtD
Fenoldopam—Urinary tract infection—Fluorouracil—pancreatic cancer	0.0026	0.00498	CcSEcCtD
Fenoldopam—Anxiety—Erlotinib—pancreatic cancer	0.0026	0.00498	CcSEcCtD
Fenoldopam—Cardiac failure—Docetaxel—pancreatic cancer	0.00257	0.00492	CcSEcCtD
Fenoldopam—Back pain—Sunitinib—pancreatic cancer	0.00257	0.00491	CcSEcCtD
Fenoldopam—Bradycardia—Irinotecan—pancreatic cancer	0.00256	0.00489	CcSEcCtD
Fenoldopam—Muscle spasms—Sunitinib—pancreatic cancer	0.00255	0.00488	CcSEcCtD
Fenoldopam—Oliguria—Epirubicin—pancreatic cancer	0.00253	0.00484	CcSEcCtD
Fenoldopam—Haemoglobin—Irinotecan—pancreatic cancer	0.00252	0.00483	CcSEcCtD
Fenoldopam—Haemorrhage—Irinotecan—pancreatic cancer	0.00251	0.0048	CcSEcCtD
Fenoldopam—Haemoglobin—Gemcitabine—pancreatic cancer	0.00246	0.0047	CcSEcCtD
Fenoldopam—Creatinine increased—Epirubicin—pancreatic cancer	0.00245	0.00469	CcSEcCtD
Fenoldopam—Haemorrhage—Gemcitabine—pancreatic cancer	0.00244	0.00468	CcSEcCtD
Fenoldopam—Hyperhidrosis—Tamoxifen—pancreatic cancer	0.00244	0.00468	CcSEcCtD
Fenoldopam—Haemoglobin—Fluorouracil—pancreatic cancer	0.00242	0.00462	CcSEcCtD
Fenoldopam—Haemorrhage—Fluorouracil—pancreatic cancer	0.0024	0.0046	CcSEcCtD
Fenoldopam—Oliguria—Doxorubicin—pancreatic cancer	0.00234	0.00448	CcSEcCtD
Fenoldopam—Flushing—Irinotecan—pancreatic cancer	0.00233	0.00446	CcSEcCtD
Fenoldopam—Injection site reaction—Epirubicin—pancreatic cancer	0.00232	0.00443	CcSEcCtD
Fenoldopam—Orthostatic hypotension—Docetaxel—pancreatic cancer	0.00229	0.00438	CcSEcCtD
Fenoldopam—Insomnia—Tamoxifen—pancreatic cancer	0.00229	0.00438	CcSEcCtD
Fenoldopam—Creatinine increased—Doxorubicin—pancreatic cancer	0.00227	0.00434	CcSEcCtD
Fenoldopam—Insomnia—Erlotinib—pancreatic cancer	0.00226	0.00433	CcSEcCtD
Fenoldopam—Chest pain—Sunitinib—pancreatic cancer	0.00226	0.00432	CcSEcCtD
Fenoldopam—Dyspnoea—Tamoxifen—pancreatic cancer	0.00225	0.00431	CcSEcCtD
Fenoldopam—Dyspnoea—Erlotinib—pancreatic cancer	0.00223	0.00427	CcSEcCtD
Fenoldopam—Blood urea increased—Epirubicin—pancreatic cancer	0.0022	0.00421	CcSEcCtD
Fenoldopam—Constipation—Tamoxifen—pancreatic cancer	0.00216	0.00414	CcSEcCtD
Fenoldopam—Injection site reaction—Doxorubicin—pancreatic cancer	0.00214	0.0041	CcSEcCtD
Fenoldopam—Constipation—Erlotinib—pancreatic cancer	0.00214	0.00409	CcSEcCtD
Fenoldopam—Back pain—Irinotecan—pancreatic cancer	0.00211	0.00405	CcSEcCtD
Fenoldopam—Angina pectoris—Docetaxel—pancreatic cancer	0.00211	0.00404	CcSEcCtD
Fenoldopam—Muscle spasms—Irinotecan—pancreatic cancer	0.0021	0.00402	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Tamoxifen—pancreatic cancer	0.00207	0.00396	CcSEcCtD
Fenoldopam—Back pain—Gemcitabine—pancreatic cancer	0.00206	0.00394	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Erlotinib—pancreatic cancer	0.00204	0.00391	CcSEcCtD
Fenoldopam—Blood urea increased—Doxorubicin—pancreatic cancer	0.00204	0.0039	CcSEcCtD
Fenoldopam—Abdominal pain—Tamoxifen—pancreatic cancer	0.002	0.00382	CcSEcCtD
Fenoldopam—Abdominal pain—Erlotinib—pancreatic cancer	0.00198	0.00378	CcSEcCtD
Fenoldopam—Body temperature increased—Erlotinib—pancreatic cancer	0.00198	0.00378	CcSEcCtD
Fenoldopam—Insomnia—Sunitinib—pancreatic cancer	0.00196	0.00375	CcSEcCtD
Fenoldopam—Dyspnoea—Sunitinib—pancreatic cancer	0.00193	0.00369	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.00191	0.00365	CcSEcCtD
Fenoldopam—Myocardial infarction—Docetaxel—pancreatic cancer	0.00189	0.00363	CcSEcCtD
Fenoldopam—Constipation—Sunitinib—pancreatic cancer	0.00185	0.00354	CcSEcCtD
Fenoldopam—Chest pain—Gemcitabine—pancreatic cancer	0.00181	0.00347	CcSEcCtD
Fenoldopam—Chest pain—Fluorouracil—pancreatic cancer	0.00178	0.00341	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Sunitinib—pancreatic cancer	0.00177	0.00339	CcSEcCtD
Fenoldopam—Haemoglobin—Docetaxel—pancreatic cancer	0.00174	0.00334	CcSEcCtD
Fenoldopam—Haemorrhage—Docetaxel—pancreatic cancer	0.00174	0.00332	CcSEcCtD
Fenoldopam—Cardiac failure—Epirubicin—pancreatic cancer	0.00173	0.00332	CcSEcCtD
Fenoldopam—Diarrhoea—Tamoxifen—pancreatic cancer	0.00173	0.00331	CcSEcCtD
Fenoldopam—Hyperhidrosis—Irinotecan—pancreatic cancer	0.00172	0.0033	CcSEcCtD
Fenoldopam—Body temperature increased—Sunitinib—pancreatic cancer	0.00171	0.00328	CcSEcCtD
Fenoldopam—Abdominal pain—Sunitinib—pancreatic cancer	0.00171	0.00328	CcSEcCtD
Fenoldopam—Diarrhoea—Erlotinib—pancreatic cancer	0.00171	0.00328	CcSEcCtD
Fenoldopam—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.00168	0.00321	CcSEcCtD
Fenoldopam—Dizziness—Tamoxifen—pancreatic cancer	0.00167	0.0032	CcSEcCtD
Fenoldopam—Tachycardia—Fluorouracil—pancreatic cancer	0.00167	0.00319	CcSEcCtD
Fenoldopam—Hypotension—Irinotecan—pancreatic cancer	0.00167	0.00319	CcSEcCtD
Fenoldopam—Dizziness—Erlotinib—pancreatic cancer	0.00165	0.00317	CcSEcCtD
Fenoldopam—Hypotension—Gemcitabine—pancreatic cancer	0.00162	0.00311	CcSEcCtD
Fenoldopam—Insomnia—Irinotecan—pancreatic cancer	0.00161	0.00309	CcSEcCtD
Fenoldopam—Flushing—Docetaxel—pancreatic cancer	0.00161	0.00308	CcSEcCtD
Fenoldopam—Vomiting—Tamoxifen—pancreatic cancer	0.00161	0.00308	CcSEcCtD
Fenoldopam—Cardiac failure—Doxorubicin—pancreatic cancer	0.0016	0.00307	CcSEcCtD
Fenoldopam—Hypotension—Fluorouracil—pancreatic cancer	0.0016	0.00305	CcSEcCtD
Fenoldopam—Vomiting—Erlotinib—pancreatic cancer	0.00159	0.00304	CcSEcCtD
Fenoldopam—Dyspnoea—Irinotecan—pancreatic cancer	0.00159	0.00304	CcSEcCtD
Fenoldopam—Blood creatinine increased—Epirubicin—pancreatic cancer	0.00158	0.00303	CcSEcCtD
Fenoldopam—Headache—Tamoxifen—pancreatic cancer	0.00158	0.00303	CcSEcCtD
Fenoldopam—Insomnia—Gemcitabine—pancreatic cancer	0.00157	0.00301	CcSEcCtD
Fenoldopam—Headache—Erlotinib—pancreatic cancer	0.00157	0.003	CcSEcCtD
Fenoldopam—Dyspnoea—Gemcitabine—pancreatic cancer	0.00155	0.00296	CcSEcCtD
Fenoldopam—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.00155	0.00296	CcSEcCtD
Fenoldopam—Insomnia—Fluorouracil—pancreatic cancer	0.00154	0.00296	CcSEcCtD
Fenoldopam—Hypokalaemia—Epirubicin—pancreatic cancer	0.00154	0.00295	CcSEcCtD
Fenoldopam—Constipation—Irinotecan—pancreatic cancer	0.00152	0.00292	CcSEcCtD
Fenoldopam—Dyspnoea—Fluorouracil—pancreatic cancer	0.00152	0.00291	CcSEcCtD
Fenoldopam—Nausea—Tamoxifen—pancreatic cancer	0.0015	0.00287	CcSEcCtD
Fenoldopam—Constipation—Gemcitabine—pancreatic cancer	0.00149	0.00284	CcSEcCtD
Fenoldopam—Nausea—Erlotinib—pancreatic cancer	0.00149	0.00284	CcSEcCtD
Fenoldopam—Diarrhoea—Sunitinib—pancreatic cancer	0.00148	0.00284	CcSEcCtD
Fenoldopam—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.00147	0.00281	CcSEcCtD
Fenoldopam—Back pain—Docetaxel—pancreatic cancer	0.00146	0.0028	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.00146	0.00279	CcSEcCtD
Fenoldopam—Muscle spasms—Docetaxel—pancreatic cancer	0.00145	0.00278	CcSEcCtD
Fenoldopam—Dizziness—Sunitinib—pancreatic cancer	0.00143	0.00274	CcSEcCtD
Fenoldopam—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.00143	0.00274	CcSEcCtD
Fenoldopam—Hypokalaemia—Doxorubicin—pancreatic cancer	0.00142	0.00273	CcSEcCtD
Fenoldopam—Angina pectoris—Epirubicin—pancreatic cancer	0.00142	0.00273	CcSEcCtD
Fenoldopam—Abdominal pain—Irinotecan—pancreatic cancer	0.00141	0.0027	CcSEcCtD
Fenoldopam—Body temperature increased—Irinotecan—pancreatic cancer	0.00141	0.0027	CcSEcCtD
Fenoldopam—Vomiting—Sunitinib—pancreatic cancer	0.00138	0.00263	CcSEcCtD
Fenoldopam—Body temperature increased—Gemcitabine—pancreatic cancer	0.00137	0.00263	CcSEcCtD
Fenoldopam—Headache—Sunitinib—pancreatic cancer	0.00136	0.0026	CcSEcCtD
Fenoldopam—Body temperature increased—Fluorouracil—pancreatic cancer	0.00135	0.00258	CcSEcCtD
Fenoldopam—Palpitations—Docetaxel—pancreatic cancer	0.00133	0.00255	CcSEcCtD
Fenoldopam—Angina pectoris—Doxorubicin—pancreatic cancer	0.00132	0.00252	CcSEcCtD
Fenoldopam—Chest pain—Docetaxel—pancreatic cancer	0.00129	0.00246	CcSEcCtD
Fenoldopam—Nausea—Sunitinib—pancreatic cancer	0.00129	0.00246	CcSEcCtD
Fenoldopam—Urinary tract infection—Epirubicin—pancreatic cancer	0.00127	0.00243	CcSEcCtD
Fenoldopam—Sweating—Epirubicin—pancreatic cancer	0.00125	0.00239	CcSEcCtD
Fenoldopam—Diarrhoea—Irinotecan—pancreatic cancer	0.00122	0.00234	CcSEcCtD
Fenoldopam—Tachycardia—Docetaxel—pancreatic cancer	0.0012	0.0023	CcSEcCtD
Fenoldopam—Bradycardia—Epirubicin—pancreatic cancer	0.00119	0.00228	CcSEcCtD
Fenoldopam—Diarrhoea—Gemcitabine—pancreatic cancer	0.00119	0.00227	CcSEcCtD
Fenoldopam—Dizziness—Irinotecan—pancreatic cancer	0.00118	0.00226	CcSEcCtD
Fenoldopam—Haemoglobin—Epirubicin—pancreatic cancer	0.00118	0.00225	CcSEcCtD
Fenoldopam—Urinary tract infection—Doxorubicin—pancreatic cancer	0.00117	0.00224	CcSEcCtD
Fenoldopam—Haemorrhage—Epirubicin—pancreatic cancer	0.00117	0.00224	CcSEcCtD
Fenoldopam—Diarrhoea—Fluorouracil—pancreatic cancer	0.00117	0.00224	CcSEcCtD
Fenoldopam—Sweating—Doxorubicin—pancreatic cancer	0.00116	0.00221	CcSEcCtD
Fenoldopam—Hypotension—Docetaxel—pancreatic cancer	0.00115	0.0022	CcSEcCtD
Fenoldopam—Vomiting—Irinotecan—pancreatic cancer	0.00113	0.00217	CcSEcCtD
Fenoldopam—Dizziness—Fluorouracil—pancreatic cancer	0.00113	0.00216	CcSEcCtD
Fenoldopam—Headache—Irinotecan—pancreatic cancer	0.00112	0.00214	CcSEcCtD
Fenoldopam—Insomnia—Docetaxel—pancreatic cancer	0.00111	0.00213	CcSEcCtD
Fenoldopam—Vomiting—Gemcitabine—pancreatic cancer	0.0011	0.00211	CcSEcCtD
Fenoldopam—Bradycardia—Doxorubicin—pancreatic cancer	0.0011	0.00211	CcSEcCtD
Fenoldopam—Dyspnoea—Docetaxel—pancreatic cancer	0.0011	0.0021	CcSEcCtD
Fenoldopam—Haemoglobin—Doxorubicin—pancreatic cancer	0.00109	0.00208	CcSEcCtD
Fenoldopam—Headache—Gemcitabine—pancreatic cancer	0.00109	0.00208	CcSEcCtD
Fenoldopam—Flushing—Epirubicin—pancreatic cancer	0.00109	0.00208	CcSEcCtD
Fenoldopam—Vomiting—Fluorouracil—pancreatic cancer	0.00109	0.00208	CcSEcCtD
Fenoldopam—Haemorrhage—Doxorubicin—pancreatic cancer	0.00108	0.00207	CcSEcCtD
Fenoldopam—Headache—Fluorouracil—pancreatic cancer	0.00107	0.00205	CcSEcCtD
Fenoldopam—Nausea—Irinotecan—pancreatic cancer	0.00106	0.00203	CcSEcCtD
Fenoldopam—Constipation—Docetaxel—pancreatic cancer	0.00105	0.00202	CcSEcCtD
Fenoldopam—Nausea—Gemcitabine—pancreatic cancer	0.00103	0.00197	CcSEcCtD
Fenoldopam—Nausea—Fluorouracil—pancreatic cancer	0.00101	0.00194	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00101	0.00193	CcSEcCtD
Fenoldopam—Flushing—Doxorubicin—pancreatic cancer	0.001	0.00192	CcSEcCtD
Fenoldopam—Tension—Epirubicin—pancreatic cancer	0.001	0.00191	CcSEcCtD
Fenoldopam—Nervousness—Epirubicin—pancreatic cancer	0.000989	0.00189	CcSEcCtD
Fenoldopam—Back pain—Epirubicin—pancreatic cancer	0.000985	0.00189	CcSEcCtD
Fenoldopam—Muscle spasms—Epirubicin—pancreatic cancer	0.000979	0.00187	CcSEcCtD
Fenoldopam—Abdominal pain—Docetaxel—pancreatic cancer	0.000974	0.00187	CcSEcCtD
Fenoldopam—Body temperature increased—Docetaxel—pancreatic cancer	0.000974	0.00187	CcSEcCtD
Fenoldopam—Tension—Doxorubicin—pancreatic cancer	0.000925	0.00177	CcSEcCtD
Fenoldopam—Nervousness—Doxorubicin—pancreatic cancer	0.000916	0.00175	CcSEcCtD
Fenoldopam—Back pain—Doxorubicin—pancreatic cancer	0.000912	0.00175	CcSEcCtD
Fenoldopam—Muscle spasms—Doxorubicin—pancreatic cancer	0.000906	0.00173	CcSEcCtD
Fenoldopam—Palpitations—Epirubicin—pancreatic cancer	0.0009	0.00172	CcSEcCtD
Fenoldopam—Chest pain—Epirubicin—pancreatic cancer	0.000867	0.00166	CcSEcCtD
Fenoldopam—Anxiety—Epirubicin—pancreatic cancer	0.000864	0.00165	CcSEcCtD
Fenoldopam—Diarrhoea—Docetaxel—pancreatic cancer	0.000843	0.00161	CcSEcCtD
Fenoldopam—Palpitations—Doxorubicin—pancreatic cancer	0.000833	0.00159	CcSEcCtD
Fenoldopam—Dizziness—Docetaxel—pancreatic cancer	0.000815	0.00156	CcSEcCtD
Fenoldopam—Tachycardia—Epirubicin—pancreatic cancer	0.000811	0.00155	CcSEcCtD
Fenoldopam—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000804	0.00154	CcSEcCtD
Fenoldopam—Chest pain—Doxorubicin—pancreatic cancer	0.000803	0.00154	CcSEcCtD
Fenoldopam—Anxiety—Doxorubicin—pancreatic cancer	0.0008	0.00153	CcSEcCtD
Fenoldopam—Vomiting—Docetaxel—pancreatic cancer	0.000784	0.0015	CcSEcCtD
Fenoldopam—Hypotension—Epirubicin—pancreatic cancer	0.000777	0.00149	CcSEcCtD
Fenoldopam—Headache—Docetaxel—pancreatic cancer	0.000772	0.00148	CcSEcCtD
Fenoldopam—Insomnia—Epirubicin—pancreatic cancer	0.000752	0.00144	CcSEcCtD
Fenoldopam—Tachycardia—Doxorubicin—pancreatic cancer	0.000751	0.00144	CcSEcCtD
Fenoldopam—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000744	0.00142	CcSEcCtD
Fenoldopam—Dyspnoea—Epirubicin—pancreatic cancer	0.000741	0.00142	CcSEcCtD
Fenoldopam—Nausea—Docetaxel—pancreatic cancer	0.000732	0.0014	CcSEcCtD
Fenoldopam—Hypotension—Doxorubicin—pancreatic cancer	0.000719	0.00138	CcSEcCtD
Fenoldopam—Constipation—Epirubicin—pancreatic cancer	0.000711	0.00136	CcSEcCtD
Fenoldopam—Insomnia—Doxorubicin—pancreatic cancer	0.000696	0.00133	CcSEcCtD
Fenoldopam—Dyspnoea—Doxorubicin—pancreatic cancer	0.000686	0.00131	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00068	0.0013	CcSEcCtD
Fenoldopam—Constipation—Doxorubicin—pancreatic cancer	0.000658	0.00126	CcSEcCtD
Fenoldopam—Abdominal pain—Epirubicin—pancreatic cancer	0.000657	0.00126	CcSEcCtD
Fenoldopam—Body temperature increased—Epirubicin—pancreatic cancer	0.000657	0.00126	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000629	0.0012	CcSEcCtD
Fenoldopam—Abdominal pain—Doxorubicin—pancreatic cancer	0.000608	0.00116	CcSEcCtD
Fenoldopam—Body temperature increased—Doxorubicin—pancreatic cancer	0.000608	0.00116	CcSEcCtD
Fenoldopam—Diarrhoea—Epirubicin—pancreatic cancer	0.000569	0.00109	CcSEcCtD
Fenoldopam—Dizziness—Epirubicin—pancreatic cancer	0.00055	0.00105	CcSEcCtD
Fenoldopam—Vomiting—Epirubicin—pancreatic cancer	0.000529	0.00101	CcSEcCtD
Fenoldopam—Diarrhoea—Doxorubicin—pancreatic cancer	0.000526	0.00101	CcSEcCtD
Fenoldopam—Headache—Epirubicin—pancreatic cancer	0.000521	0.000997	CcSEcCtD
Fenoldopam—Dizziness—Doxorubicin—pancreatic cancer	0.000509	0.000974	CcSEcCtD
Fenoldopam—Nausea—Epirubicin—pancreatic cancer	0.000494	0.000945	CcSEcCtD
Fenoldopam—Vomiting—Doxorubicin—pancreatic cancer	0.000489	0.000936	CcSEcCtD
Fenoldopam—Headache—Doxorubicin—pancreatic cancer	0.000482	0.000923	CcSEcCtD
Fenoldopam—Nausea—Doxorubicin—pancreatic cancer	0.000457	0.000875	CcSEcCtD
Fenoldopam—DRD5—Signaling Pathways—EGFR—pancreatic cancer	4.63e-05	9.69e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—EGF—pancreatic cancer	4.63e-05	9.69e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PIK3CG—pancreatic cancer	4.62e-05	9.67e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—APOE—pancreatic cancer	4.61e-05	9.64e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TERT—pancreatic cancer	4.58e-05	9.6e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—PIK3CA—pancreatic cancer	4.52e-05	9.46e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—KDR—pancreatic cancer	4.51e-05	9.45e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PIK3CD—pancreatic cancer	4.48e-05	9.37e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—PIK3CA—pancreatic cancer	4.46e-05	9.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PPARG—pancreatic cancer	4.46e-05	9.34e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NFKBIA—pancreatic cancer	4.46e-05	9.33e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.43e-05	9.28e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NOTCH1—pancreatic cancer	4.41e-05	9.24e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—HIF1A—pancreatic cancer	4.38e-05	9.18e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—KRAS—pancreatic cancer	4.38e-05	9.17e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—PIK3CB—pancreatic cancer	4.38e-05	9.17e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TSC2—pancreatic cancer	4.37e-05	9.16e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—KRAS—pancreatic cancer	4.37e-05	9.16e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PIK3CB—pancreatic cancer	4.36e-05	9.12e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Hemostasis—AKT1—pancreatic cancer	4.35e-05	9.1e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—EGFR—pancreatic cancer	4.33e-05	9.07e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—PIK3CB—pancreatic cancer	4.32e-05	9.05e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PTGS2—pancreatic cancer	4.32e-05	9.04e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CG—pancreatic cancer	4.31e-05	9.03e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—NRAS—pancreatic cancer	4.31e-05	9.03e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	4.29e-05	8.99e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	4.28e-05	8.96e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—EGF—pancreatic cancer	4.26e-05	8.93e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—EGFR—pancreatic cancer	4.26e-05	8.93e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	4.25e-05	8.9e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—CXCL8—pancreatic cancer	4.21e-05	8.81e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	4.19e-05	8.78e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—HRAS—pancreatic cancer	4.18e-05	8.75e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PIK3CD—pancreatic cancer	4.18e-05	8.75e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	4.16e-05	8.7e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	4.16e-05	8.7e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—CXCL8—pancreatic cancer	4.15e-05	8.69e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.14e-05	8.67e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—HRAS—pancreatic cancer	4.13e-05	8.64e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PIK3CD—pancreatic cancer	4.11e-05	8.61e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	4.11e-05	8.6e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—KRAS—pancreatic cancer	4.09e-05	8.57e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—GPCR downstream signaling—PIK3CA—pancreatic cancer	4.08e-05	8.53e-05	CbGpPWpGaD
Fenoldopam—DRD1—GPCR downstream signaling—AKT1—pancreatic cancer	4.07e-05	8.51e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	4.06e-05	8.5e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—KRAS—pancreatic cancer	4.03e-05	8.43e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—CASP3—pancreatic cancer	4.03e-05	8.43e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—PIK3CA—pancreatic cancer	4.03e-05	8.43e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—PIK3CA—pancreatic cancer	4.02e-05	8.41e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—GPCR downstream signaling—AKT1—pancreatic cancer	4.01e-05	8.4e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	3.99e-05	8.35e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—CASP3—pancreatic cancer	3.97e-05	8.32e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	3.95e-05	8.27e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—EGFR—pancreatic cancer	3.93e-05	8.23e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—CCND1—pancreatic cancer	3.92e-05	8.21e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PIK3CB—pancreatic cancer	3.9e-05	8.17e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—TP53—pancreatic cancer	3.89e-05	8.14e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—CTNNB1—pancreatic cancer	3.88e-05	8.13e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—CCND1—pancreatic cancer	3.87e-05	8.1e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	3.86e-05	8.09e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	3.86e-05	8.09e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—CTNNB1—pancreatic cancer	3.83e-05	8.02e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	3.82e-05	7.99e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—MMP9—pancreatic cancer	3.81e-05	7.97e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CD—pancreatic cancer	3.79e-05	7.94e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	3.79e-05	7.93e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—PTEN—pancreatic cancer	3.78e-05	7.92e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PTEN—pancreatic cancer	3.77e-05	7.88e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—PIK3CA—pancreatic cancer	3.76e-05	7.87e-05	CbGpPWpGaD
Fenoldopam—DRD2—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.76e-05	7.87e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—MMP9—pancreatic cancer	3.76e-05	7.86e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CXCL8—pancreatic cancer	3.75e-05	7.85e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—PTEN—pancreatic cancer	3.73e-05	7.82e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—HRAS—pancreatic cancer	3.72e-05	7.8e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—HRAS—pancreatic cancer	3.72e-05	7.78e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—KRAS—pancreatic cancer	3.71e-05	7.78e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—PIK3CA—pancreatic cancer	3.7e-05	7.75e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—AKT1—pancreatic cancer	3.69e-05	7.73e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	3.65e-05	7.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PIK3CB—pancreatic cancer	3.64e-05	7.63e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—AKT1—pancreatic cancer	3.64e-05	7.63e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—GPCR downstream signaling—AKT1—pancreatic cancer	3.62e-05	7.58e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.62e-05	7.58e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CASP3—pancreatic cancer	3.59e-05	7.51e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PIK3CB—pancreatic cancer	3.59e-05	7.51e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	3.58e-05	7.49e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	3.54e-05	7.41e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	3.52e-05	7.37e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—SRC—pancreatic cancer	3.51e-05	7.35e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PTGS2—pancreatic cancer	3.51e-05	7.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CXCL8—pancreatic cancer	3.5e-05	7.33e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CCND1—pancreatic cancer	3.49e-05	7.31e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—HRAS—pancreatic cancer	3.48e-05	7.28e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—SRC—pancreatic cancer	3.46e-05	7.25e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CTNNB1—pancreatic cancer	3.46e-05	7.24e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CXCL8—pancreatic cancer	3.45e-05	7.22e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—HRAS—pancreatic cancer	3.42e-05	7.17e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—VEGFA—pancreatic cancer	3.42e-05	7.16e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—PIK3CA—pancreatic cancer	3.41e-05	7.14e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	3.4e-05	7.11e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—MMP9—pancreatic cancer	3.39e-05	7.1e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—STAT3—pancreatic cancer	3.38e-05	7.09e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—GPCR downstream signaling—AKT1—pancreatic cancer	3.38e-05	7.08e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—NRAS—pancreatic cancer	3.38e-05	7.07e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—VEGFA—pancreatic cancer	3.37e-05	7.06e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PTEN—pancreatic cancer	3.37e-05	7.06e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	3.36e-05	7.04e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CASP3—pancreatic cancer	3.35e-05	7.02e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—STAT3—pancreatic cancer	3.34e-05	6.99e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—NRAS—pancreatic cancer	3.33e-05	6.97e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—GPCR downstream signaling—AKT1—pancreatic cancer	3.33e-05	6.97e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	3.32e-05	6.96e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CB—pancreatic cancer	3.31e-05	6.92e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CASP3—pancreatic cancer	3.3e-05	6.91e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—AKT1—pancreatic cancer	3.29e-05	6.89e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.29e-05	6.88e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—AKT1—pancreatic cancer	3.28e-05	6.87e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CCND1—pancreatic cancer	3.26e-05	6.83e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	3.23e-05	6.76e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	3.21e-05	6.72e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	3.19e-05	6.67e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	3.18e-05	6.66e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	3.18e-05	6.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	3.17e-05	6.63e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	3.16e-05	6.61e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	3.15e-05	6.59e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—MYC—pancreatic cancer	3.14e-05	6.58e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	3.14e-05	6.57e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	3.13e-05	6.55e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	3.12e-05	6.53e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	3.1e-05	6.5e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	3.1e-05	6.49e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	3.1e-05	6.48e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—EGFR—pancreatic cancer	3.08e-05	6.44e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	3.07e-05	6.43e-05	CbGpPWpGaD
Fenoldopam—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	3.07e-05	6.43e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	3.06e-05	6.41e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PTEN—pancreatic cancer	3.06e-05	6.4e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	3.05e-05	6.4e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	3.04e-05	6.37e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	3.04e-05	6.37e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CASP3—pancreatic cancer	3.04e-05	6.37e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	3.03e-05	6.35e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	3.02e-05	6.33e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	3.01e-05	6.31e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	3.01e-05	6.3e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CCND1—pancreatic cancer	2.96e-05	6.2e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	2.96e-05	6.2e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	2.96e-05	6.19e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	2.93e-05	6.14e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	2.93e-05	6.13e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	2.92e-05	6.11e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—KRAS—pancreatic cancer	2.91e-05	6.08e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	2.87e-05	6.02e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MMP9—pancreatic cancer	2.87e-05	6.02e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	2.87e-05	6e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PTEN—pancreatic cancer	2.86e-05	5.98e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	2.85e-05	5.97e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	2.84e-05	5.96e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	2.84e-05	5.95e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	2.83e-05	5.92e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	2.82e-05	5.91e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	2.82e-05	5.9e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	2.81e-05	5.88e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	2.8e-05	5.87e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	2.8e-05	5.86e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	2.79e-05	5.85e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	2.79e-05	5.84e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	2.77e-05	5.8e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	2.77e-05	5.8e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	2.76e-05	5.79e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	2.75e-05	5.76e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	2.75e-05	5.75e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	2.74e-05	5.74e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	2.72e-05	5.7e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	2.69e-05	5.62e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	2.67e-05	5.59e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	2.66e-05	5.56e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	2.65e-05	5.55e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—SRC—pancreatic cancer	2.65e-05	5.55e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	2.63e-05	5.52e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	2.62e-05	5.49e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	2.62e-05	5.48e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	2.61e-05	5.47e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	2.59e-05	5.42e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—TP53—pancreatic cancer	2.58e-05	5.41e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	2.58e-05	5.4e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	2.58e-05	5.39e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	2.57e-05	5.39e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	2.57e-05	5.38e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	2.56e-05	5.36e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	2.56e-05	5.36e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—STAT3—pancreatic cancer	2.56e-05	5.35e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	2.55e-05	5.34e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NRAS—pancreatic cancer	2.55e-05	5.34e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	2.55e-05	5.34e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	2.52e-05	5.27e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	2.49e-05	5.22e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	2.49e-05	5.21e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—HRAS—pancreatic cancer	2.47e-05	5.17e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	2.46e-05	5.15e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	2.46e-05	5.14e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	2.44e-05	5.1e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	2.42e-05	5.06e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	2.38e-05	4.98e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	2.38e-05	4.98e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MYC—pancreatic cancer	2.37e-05	4.97e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	2.37e-05	4.97e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	2.37e-05	4.96e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—EGFR—pancreatic cancer	2.32e-05	4.86e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	2.31e-05	4.84e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	2.3e-05	4.82e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	2.29e-05	4.79e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	2.29e-05	4.79e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	2.28e-05	4.78e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	2.28e-05	4.78e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	2.24e-05	4.68e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	2.22e-05	4.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	2.2e-05	4.61e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—KRAS—pancreatic cancer	2.19e-05	4.59e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	2.19e-05	4.58e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—AKT1—pancreatic cancer	2.18e-05	4.57e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—AKT1—pancreatic cancer	2.17e-05	4.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	2.16e-05	4.52e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	2.15e-05	4.51e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	2.15e-05	4.5e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	2.13e-05	4.45e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	2.12e-05	4.44e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	2.11e-05	4.43e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	2.11e-05	4.43e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	2.08e-05	4.35e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	2.06e-05	4.3e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	2.02e-05	4.24e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	2.02e-05	4.22e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	1.96e-05	4.11e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—TP53—pancreatic cancer	1.95e-05	4.08e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	1.94e-05	4.07e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	1.94e-05	4.07e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	1.88e-05	3.93e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—HRAS—pancreatic cancer	1.86e-05	3.9e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	1.81e-05	3.8e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	1.8e-05	3.78e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	1.8e-05	3.76e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	1.79e-05	3.74e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—AKT1—pancreatic cancer	1.76e-05	3.69e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	1.75e-05	3.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	1.67e-05	3.5e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—AKT1—pancreatic cancer	1.65e-05	3.45e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	1.59e-05	3.32e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	1.47e-05	3.09e-05	CbGpPWpGaD
